Catch up on the latest updates from #Binance Wallet:1. ARIA, SAPIEN, DGC, DAM, WILD, MLK and TCOM were featured on Binance Alpha with exclusive airdrops for eligible users 🎁2. 8 Ongoing Booster Campaigns with Codatta, Mitosis, OpenEden, Bitlayer, Hemi, BAS and Reveel 💰3. Binance Wallet (Web) feedback campaign live until Aug 29 🚀4. Binance Alpha trading Competition with $3M rewards up for grabs 🔥5. Exclusive Bonding Curve Token Generation Event (TGE) with AKEDO (AKE) ...

Surprise airdrop for #BGB holders, $500 TCOM + $500 SAPIEN up for grabs! 🪂👥 Top 200 active chatters (Aug 14–20) share $500 TCOM🆕 New users join BGB holders group get $10 SAPIEN each – FCFS!How to join:1️⃣ Hold at least 10 BGB2️⃣ Use the verification bot to join the BGB Holder Group: https://t.co/KHxdmewDYT3️⃣ Submit the registration form: https://t.co/rOpKcSsiya ...

$SAPIEN @JoinSapien trading is now LIVE on #BitgetSpot.🚀 Trade now: https://t.co/fHFx4eklzUBitget (@bitgetglobal):Initial Listing - $SAPIEN @joinsapien🔹Pair: SAPIEN/USDT🔹Deposit available: Now🔹Trading available: Aug 20, 17:00 (UTC)Details: https://t.co/Y3rvrhIwqN https://t.co/kfREeSEWmr ...

Summary of Edwards Lifesciences (EW) Conference Call Company Overview - **Company**: Edwards Lifesciences (EW) - **Industry**: Medical Devices, specifically focusing on heart valve technologies and related innovations Key Points and Arguments Financial Performance and Guidance - **Q4 and Q1 Performance**: Strong performance in Q4 and Q1, maintaining guidance for 2025 with revenue growth expected between 8% to 10% and EPS between $2.4 to $2.5 [5][11] - **Long-term Growth Commitment**: Aiming for double-digit growth (10%+) starting in 2026, with EPS growth expected to outpace revenue growth [11][12] Product Innovations and Market Opportunities - **TAVR (Transcatheter Aortic Valve Replacement)**: Early approval for TAVR expected to drive multi-year growth opportunities; significant patient benefits anticipated from new technologies [6][30] - **EVOQUE Technology**: CE Mark approval for the first transcatheter mitral replacement in Europe; strong data presented on Resilia technology [6][7] - **Emerging Opportunities**: Acquisition of Jesse Medical and ongoing pivotal studies in heart failure technologies [7][8] Supply Chain and Tariff Impact - **Supply Chain Resilience**: Global supply chain footprint is robust, with minimal impact from tariffs; the company is well-protected against tariff fluctuations [13][14][16] - **Tariff Impact on EPS**: Estimated impact of tariffs on EPS is around $0.05 per share, with more significant effects expected in 2026 [15] NCD (National Coverage Determination) and Regulatory Environment - **NCD Reopening for TAVR**: Anticipation that CMS will reopen the NCD for TAVR based on solid data and the procedure's established status as standard care [25][26] - **Guideline Changes**: Ongoing policy and guideline changes expected to further support TAVR growth [30][39] Training and Market Penetration - **Training for EVOQUE Centers**: Significant demand for EVOQUE centers; training processes in place to ensure rapid onboarding of new centers [51][55] - **Market Awareness**: Efforts underway to educate physicians on new data and implications for practice, aiming to drive referrals to interventionalists [34][40] Acquisitions and Future Growth - **Strategic Acquisitions**: Recent acquisitions (Endotronic, InnoValve, Jesse Medical) are expected to enhance the company's portfolio and address various heart conditions [61][63] - **Long-term Vision**: Commitment to long-term growth in structural heart disease, with expectations for significant contributions from new technologies [50][62] Additional Important Insights - **Leadership and Execution**: Strong leadership team noted for effective management of financial performance and strategic priorities [20][22] - **Patient-Centric Approach**: Emphasis on patient care and outcomes as a core value of the company, beyond just business metrics [37][59] This summary encapsulates the key discussions and insights from the Edwards Lifesciences conference call, highlighting the company's financial outlook, product innovations, market strategies, and commitment to patient care.